User menu

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.

Bibliographic reference Kalincik, Tomas ; Spelman, Timothy ; Trojano, Maria ; Duquette, Pierre ; Izquierdo, Guillermo ; et. al. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.. In: PLoS One, Vol. 8, no.5, p. e63480 (2013)
Permanent URL http://hdl.handle.net/2078.1/135827
  1. Butzkueven H, Chapman J, Cristiano E, Grand’Maison F, Hoffmann M, Izquierdo G, Jolley D, Kappos L, Leist T, Pöhlau D, Rivera V, Trojano M, Verheul F, Malkowski J-P, MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis, 10.1177/1352458506070775
  2. M Trojano, Int MS J, 16, 90 (2009)
  3. Rosenbaum Paul R., Rubin Donald B., Reducing Bias in Observational Studies Using Subclassification on the Propensity Score, 10.1080/01621459.1984.10478078
  4. Lunceford Jared K., Davidian Marie, Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study, 10.1002/sim.1903
  5. Trojano Maria, Pellegrini Fabio, Fuiani Aurora, Paolicelli Damiano, Zipoli Valentina, Zimatore Giovanni B., Di Monte Elisabetta, Portaccio Emilio, Lepore Vito, Livrea Paolo, Amato Maria Pia, New natural history of interferon-β-treated relapsing multiple sclerosis, 10.1002/ana.21102
  6. Goodin Douglas S., Jones Jason, Li David, Traboulsee Anthony, Reder Anthony T., Beckmann Karola, Konieczny Andreas, Knappertz Volker, , Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS, 10.1371/journal.pone.0022444
  7. Conway Devon S, Miller Deborah M, O’Brien Ralph G, Cohen Jeffrey A, Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique, 10.1177/1352458512449681
  8. Ebers George C, Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis, 10.1016/s0140-6736(98)03334-0
  9. DE Ho, Political Analysis, 15, 199 (2006)
  10. XS Gu, J Comput Graph Stat, 4, 405 (1993)
  11. King Gary, Zeng Langche, The Dangers of Extreme Counterfactuals, 10.1093/pan/mpj004
  12. Panitch H., Goodin D.S., Francis G., Chang P., Coyle P.K., O'Connor P., Monaghan E., Li D., Weinshenker B., Randomized, comparative study of interferon  -1a treatment regimens in MS: The EVIDENCE Trial, 10.1212/01.wnl.0000034080.43681.da
  13. Lublin F, Cofield S, Cutter G, Conwit R, Narayana P, et al.. (2013) Randomized study combining interferon & glatiramer acetate in multiple sclerosis. Annals of neurology in press.
  14. Cohen Jeffrey A, Coles Alasdair J, Arnold Douglas L, Confavreux Christian, Fox Edward J, Hartung Hans-Peter, Havrdova Eva, Selmaj Krzysztof W, Weiner Howard L, Fisher Elizabeth, Brinar Vesna V, Giovannoni Gavin, Stojanovic Miroslav, Ertik Bella I, Lake Stephen L, Margolin David H, Panzara Michael A, Compston D Alastair S, Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial, 10.1016/s0140-6736(12)61769-3
  15. Shirani Afsaneh, Zhao Yinshan, Karim Mohammad Ehsanul, Evans Charity, Kingwell Elaine, van der Kop Mia L., Oger Joel, Gustafson Paul, Petkau John, Tremlett Helen, Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis, 10.1001/jama.2012.7625
  16. Prosperini Luca, Giannì Costanza, Leonardi Laura, De Giglio Laura, Borriello Giovanna, Galgani Simonetta, Pozzilli Carlo, Gasperini Claudio, Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis, 10.1177/1352458511417481
  17. Trojano Maria, Russo Pierluigi, Fuiani Aurora, Paolicelli Damiano, Di Monte Elisabetta, Granieri Enrico, Rosati Giulio, Savettieri Giovanni, Comi Giancarlo, Livrea Paolo, , The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNβ exposure in multiple sclerosis, 10.1177/1352458506070620
  18. Trojano M., Pellegrini F., Paolicelli D., Fuiani A., Zimatore G.B., Tortorella C., Simone I.L., Patti F., Ghezzi A., Zipoli V., Rossi P., Pozzilli C., Salemi G., Lugaresi A., Bergamaschi R., Millefiorini E., Clerico M., Lus G., Vianello M., Avolio C., Cavalla P., Lepore V., Livrea P., Comi G., Amato M.P., , Real-life impact of early interferonβ therapy in relapsing multiple sclerosis : Early IFNβ Treatment in RRMS, 10.1002/ana.21757
  19. Trojano M., Pellegrini F., Paolicelli D., Fuiani A., Zimatore G.B., Tortorella C., Simone I.L., Patti F., Ghezzi A., Portaccio E., Rossi P., Pozzilli C., Salemi G., Lugaresi A., Bergamaschi R., Millefiorini E., Clerico M., Lus G., Vianello M., Avolio C., Cavalla P., Iaffaldano P., Direnzo V., D'Onghia M., Lepore V., Livrea P., Comi G., Amato M.P., Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment, 10.1016/j.jns.2009.06.036
  20. Meyniel Claire, Spelman Timothy, Jokubaitis Vilija G., Trojano Maria, Izquierdo Guillermo, Grand’Maison François, Oreja-Guevara Celia, Boz Cavit, Lugaresi Alessandra, Girard Marc, Grammond Pierre, Iuliano Gerardo, Fiol Marcela, Cabrera-Gomez Jose Antonio, Fernandez-Bolanos Ricardo, Giuliani Giorgio, Lechner-Scott Jeannette, Cristiano Edgardo, Herbert Joseph, Petkovska-Boskova Tatjana, Bergamaschi Roberto, van Pesch Vincent, Moore Fraser, Vella Norbert, Slee Mark, Santiago Vetere, Barnett Michael, Havrdova Eva, Young Carolyn, Sirbu Carmen-Adella, Tanner Mary, Rutherford Michelle, Butzkueven Helmut, , Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome, 10.1371/journal.pone.0038661